SPHK2 and plasma cell myeloma: Inhibition of SK2 by ABC294640 effectively suppressed the myeloma growth in vitro and in vivo.4 A phase I/II clinical trial of single agent ABC294640 in relapsed and refractory myeloma patients is currently ongoing (http://www.clinicaltrials.gov: #NCT01410981).